# PLX-66140

Source: https://onco.cc/drugs/plx-66140/  
OnCo record `plx-66140` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PLX-66140 is an experimental oral molecular glue degrader from Plexium, in preclinical development for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours.

## Summary

PLX-66140 is an oral molecular glue degrader (cereblon) from Plexium. A cereblon-based molecular glue that degrades CDK2, aimed at tumours driven by cyclin E (CCNE1) amplification or overexpression. Its furthest stage is preclinical development, for ER-positive/HER2-negative breast cancer and CCNE1-amplified tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical on company pipeline chart. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: PLX-66140
- Modality: Oral molecular glue degrader (cereblon)
- Mechanism: A cereblon-based molecular glue that degrades CDK2, aimed at tumours driven by cyclin E (CCNE1) amplification or overexpression.

## Sources

- Plexium: plexium.com: https://plexium.com/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [Plexium](https://onco.cc/companies/plexium/)

---
JSON: https://onco.cc/api/v1/entities/plx-66140.json